Brett Marshall is the Corporate Head, Quality Assurance for Zuellig Pharma, the largest healthcare services group in Asia. Based in Singapore, Brett has direct reporting lines from Quality Assurance Heads in 13 Countries and Quality oversight of Clinical Reach Operations in another 4 Countries.
Brett is a strong advocate of the exciting agenda of change for the Quality landscape and driving more effective risk management in the Cold Chain, Supplier Management, and the digitization opportunities driving to Industry 4.0 in the Quality space.
Originally from Melbourne, Australia, Brett has a Bachelor Degree in Transport & Logistics Management from RMIT. He has 25 years’ experience in Executive Management, Logistics & Supply Chain, Business Process Transformation and Quality Assurance, 15 years in the Pharma Industry, and more than 20 years living in Asia, in Indonesia, Thailand, the Philippines, Bangladesh and now Singapore.
Besides the FDA data integrity guidance, around the globe pharmaceutical manufacturers are faced with a multitude of regulatory requirements, updates, a changing landscape and increased requirements, many times having immediate impact on manufacturing processes, the supply chain and organizations.
Innovation has also impacted manufacturing IT such as MES, packaging systems, data capture and monitoring, GPS tracking, and focuses on end to end IT capabilities for quality management, among others.
Learn about the trends that will influence the future pharma value chains and how “right the first time”, data integrity and manufacturing intelligence can become a reality in a changing regulatory landscape.